Tobias Harm
Overview
Explore the profile of Tobias Harm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El Bounkari O, Zan C, Yang B, Ebert S, Wagner J, Bugar E, et al.
Nat Commun
. 2025 Mar;
16(1):2297.
PMID: 40055309
Atherosclerosis is the underlying cause of myocardial infarction and ischemic stroke. It is a lipid-triggered and cytokine/chemokine-driven arterial inflammatory condition. We identify D-dopachrome tautomerase/macrophage migration-inhibitory factor-2 (MIF-2), a paralog of...
2.
Appenzeller F, Harm T, Sigle M, Aidery P, Kreisselmeier K, Baas L, et al.
ESC Heart Fail
. 2025 Jan;
PMID: 39834126
Aims: Heart failure (HF) patients may lack improvement of left ventricular (LV) ejection fraction (LVEF) despite optimal HF medication comprising an angiotensin receptor-neprilysin inhibitor (ARNI). Therefore, we aimed to identify...
3.
Schaale D, Laspa Z, Balmes A, Sigle M, Dicenta-Baunach V, Hochuli R, et al.
FASEB J
. 2024 Nov;
38(21):e70155.
PMID: 39530531
Platelet activation plays a critical role in thrombosis and hemostasis. Several pathophysiological situations lead to hemolysis, resulting in the liberation of free ferric iron-containing hemin. Hemin has been shown to...
4.
Laspa Z, Dicenta-Baunach V, Schaale D, Sigle M, Hochuli R, Castor T, et al.
FEBS J
. 2024 Oct;
291(24):5420-5434.
PMID: 39387619
In vulnerable atherosclerotic plaques, intraplaque hemorrhages (IPH) result in hemolysis of red blood cells and release of hemoglobin and free hemin. Hemin activates platelets and leads to thrombosis. Agonism of...
5.
Harm T, Schwarz F, Zdanyte M, Goldschmied A, Baas L, Aidery P, et al.
Sci Rep
. 2024 Sep;
14(1):22067.
PMID: 39333219
A precise quantification of mitral regurgitation (MR) severity is essential for treatment and outcome of patients with MR. 3D echocardiography facilitates estimation of MR but selection of patients with necessity...
6.
Harm T, Mueller K, Geisler T
Interv Cardiol Clin
. 2024 Sep;
13(4):451-467.
PMID: 39245546
Antiplatelet and anticoagulant therapies are cornerstones of secondary prevention in high-risk cardiovascular patients. Whereas in former days the focus was set on effective antithrombotic effects, more recent trials and guidelines...
7.
de Jonckheere B, Kollotzek F, Munzer P, Gob V, Fischer M, Mott K, et al.
Nat Cardiovasc Res
. 2024 Aug;
2(12):1327.
PMID: 39196157
No abstract available.
8.
Gunter M, Mueller K, Salazar M, Gekeler S, Prang C, Harm T, et al.
Eur J Immunol
. 2024 Aug;
54(11):e2451145.
PMID: 39094122
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection can lead to life-threatening clinical manifestations. Patients with cardiovascular disease (CVD) are at higher risk for severe courses of COVID-19. So...
9.
Mueller K, Langnau C, Harm T, Sigle M, Mott K, Droppa M, et al.
Arterioscler Thromb Vasc Biol
. 2024 Jul;
44(9):2118-2135.
PMID: 38989580
Background: Aortic stenosis (AS) is driven by progressive inflammatory and fibrocalcific processes regulated by circulating inflammatory and valve resident endothelial and interstitial cells. The impact of platelets, platelet-derived mediators, and...
10.
Harm T, Fu X, Frey M, Dittrich K, Brun A, Castor T, et al.
Sci Rep
. 2024 Mar;
14(1):6089.
PMID: 38480746
Coronary artery disease (CAD) often leads to adverse events resulting in significant disease burdens. Underlying risk factors often remain inapparent prior to disease incidence and the cardiovascular (CV) risk is...